This database contains 34 studies, archived under the term: "executive function"
Click here to filter this large number of results.
Impaired glucose metabolism slows executive function independent of cerebral ischemic lesions in Japanese elderly: the Takahata study
Takahashi, Yoshimi,
Iseki, Chifumi,
Wada, Manabu,
Momma, Tadasuke,
Ueki, Masao,
Kawanami, Toru,
Daimon, Makoto,
Suzuki, Kyoko,
Tamiya, Gen,
Kato, Takeo
Objective: Age is known to influence the risk of both cerebral ischemic lesions and impaired cognitive function. Diabetes mellitus (DM) can also be associated with cognitive impairment. However, there has been no study of neuropsychological performance in association with glucose metabolism status and cerebral ischemic lesions in same-aged, community-dwelling elderly persons. The present study was […]
Cognitive subdomain responses to galantamine in Alzheimer’s disease
Song, Jihye,
Ahn, Inn Sook,
Kang, Hyo Shin,
Myung, Woojae,
Lee, Yujin,
Woo, Sook-young,
Ku, Hyoung Mo,
Hwang, Tae-Young,
Carroll, Bernard J.,
Kim, Doh Kwan
We investigated the effects of galantamine on cognitive subdomains in Alzheimer’s disease (AD). Sixty-six patients with mild-to-moderate AD received open-label galantamine for 52 weeks. Cognitive function was measured using the Korean version of the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog-K). Response to galantamine was defined as “improvement or no deterioration” on the total scores of […]
Alzheimer’s disease (AD) and executive dysfunction. A case-control study on the significance of frontal white matter changes detected by diffusion tensor imaging (DTI)
Sjöbeck, Martin,
Elfgren, Christina,
Larsson, Elna-Marie,
Brockstedt, Sara,
Lätt, Jimmy,
Englund, Elisabet,
Passant, Ulla
White matter (WM) changes are frequently seen on structural imaging in AD but the clinical relevance of these changes is uncertain. Frontal WM pathology is often observed upon neuropathological examination in AD. Since frontal cortical/sub-cortical pathology is known to relate to executive dysfunction, the aim was to elucidate if frontal WM changes in AD correlated […]
Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study
Simioni, S.,
Cavassini, M.,
Annoni, J.-M.,
Metral, M.,
Iglesias, K.,
Rimbault Abraham, A.,
Jilek, S.,
Calmy, A.,
Muller, H.,
Fayet-Mello, A.,
Giacobini, E.,
Hirschel, B.,
Du Pasquier, R. A.
Objective: To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV+ patients.; Methods: Seventeen aviremic HIV+ patients with HAND were enrolled in a randomized, double-blind, placebo-controlled, crossover study to receive either oral rivastigmine (up to 12 mg/day for 20 weeks) followed by […]
A randomized controlled trial of estrogen treatment in men with mild cognitive impairment
This randomized, placebo-controlled, cross-over study investigated whether estrogen treatment would have a beneficial effect on tests of verbal memory in men with mild cognitive impairment (MCI). Forty-three men newly diagnosed with MCI were administered a battery of neuropsychological tests before randomly receiving 12 weeks of treatment with estrogen or placebo followed by a 12 week […]
Donepezil improves gait performance in older adults with mild Alzheimer’s disease: A phase II clinical trial
Montero-Odasso, Manuel,
Muir-Hunter, Susan W.,
Oteng-Amoako, Afua,
Gopaul, Karen,
Islam, Anam,
Borrie, Michael,
Wells, Jennie,
Speechley, Mark
Background: Gait deficits are prevalent in people with dementia and increase their fall risk and future disability. Few treatments exist for gait impairment in Alzheimer’s disease (AD) but preliminary studies have shown that cognitive enhancers may improve gait in this population. Objective: To determine the efficacy of donepezil, a cognitive enhancer that improves cholinergic activity, […]
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease
Grove, Richard A.,
Harrington, Conn M.,
Mahler, Andreas,
Beresford, Isabel,
Maruff, Paul,
Lowy, Martin T.,
Nicholls, Andrew P.,
Boardley, Rebecca L.,
Berges, Alienor C.,
Nathan, Pradeep J.,
Horrigan, Joseph P.
Introduction: Histaminergic H3 receptors may play a role in modulating cholinergic and monoaminergic neurotransmission. This Phase II study evaluated the efficacy and safety of GSK239512, a highly potent, brain penetrant H3 receptor antagonist as monotherapy treatment for subjects with mild-to-moderate probable Alzheimer’s disease (AD).; Methods: In this 16-week, double-blind, randomized, parallel group study, 196 currently […]
Can a memory club help maintain cognitive function? A pilot investigation
Fritsch, Thomas,
McClendon, McKee J.,
Wallendal, Maggie S.,
Smyth, Kathleen A.,
Geldmacher, David S.,
Hyde, Trevor F.,
Leo, Gary J.
In a pilot investigation we evaluated the impact of a structured early memory loss (EML) program intervention in a longitudinal (repeated measures) study of 55 persons with mild cognitive impairment or mild dementia. At four test sites we examined whether participation in the club—which sought to stimulate mental activity and social interaction, provide opportunities for […]
The effect of midlife physical activity on cognitive function among older adults: AGES–Reykjavik Study
Chang, M.,
Jonsson, P. V.,
Snaedal, J.,
Bjornsson, S.,
Saczynski, J. S.,
Aspelund, T.,
Eiriksdottir, G.,
Jonsdottir, M. K.,
Lopez, O. L.,
Harris, T. B.,
Gudnason, V.,
Launer, L. J.
Background: There are few studies on the long-term associations of physical activity (PA) to cognition. Here, we examine the association of midlife PA to late-life cognitive function and dementia.; Methods: The sample consisted of a population-based cohort of men and women (born in 1907-1935) participating in the Age Gene/Environment Susceptibility-Reykjavik Study. The interval between the […]